dermatologyadvisor11h
Positive Results for Tremfya in Low Body Surface Area Psoriasis
Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.
J&J and Lilly both boast IL-23 inhibitor efficacy in Crohn’s disease
After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...
JNJ's subcutaneous Tremfya demonstrates efficacy in Crohn's
A phase 3 study found that a subcutaneous version of Johnson & Johnson's Tremfya (guselkumab) was effective in treating Crohn ...
Johnson & Johnson’s Tremfya shows efficacy in Crohn’s disease Phase 3 study
Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya – guselkumab -, the first and only IL-23 inhibitor, ...
Johnson & Johnson reports results from Phase 3b SPECTREM study
Johnson & Johnson announced that treatment with TREMFYA, or guselkumab, resulted in clear or almost clear skin in the majority of adults ...
The Pharma Letter4d
Positive results for J&J’s Tremfya in plaque psoriasis
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface ...
The American Journal of Managed Care4d
Guselkumab Clears Skin in Psoriasis Resistant to Topicals
New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.
FiercePharma4d
J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups
Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...
New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...